<DOC>
	<DOC>NCT02149706</DOC>
	<brief_summary>Multi-center, randomized , double-blind, placebo-controlled , two arm parallel design study of NeuroVax™ vs. Incomplete Freund's Adjuvant ( I F A) placebo. 150 subjects with Secondary Progressive SPMS.</brief_summary>
	<brief_title>A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis</brief_title>
	<detailed_description>The primary objective is to compare between treatment groups the Measures of neurologic disability EDSS scores.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Freund's Adjuvant</mesh_term>
	<criteria>Ages Eligible for Study: 18 Years to 70 Years Genders Eligible for Study: Both Accepts Healthy Volunteers: No Criteria Subject is between 18 and 70 years of age, inclusive. Definite MS by the revised McDonald criteria (2005) (Appendix A), with a Secondary Progressive course. Expanded Disability Status Scale (EDSS) &gt;=score 3.5 (Appendix B). Two or more documented clinical relapses of MS in the preceding 24 months OR one documented clinical relapse of MS in the preceding 1 2 months prior to screening . Laboratory values within the following limits: Creatinine 1 . 5 x high normal. Hemoglobin Subjects currently prescribed Campath or Lemtrada</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Secondary Progress Multiple Sclerosis</keyword>
	<keyword>SPMS</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>NeuroVax</keyword>
</DOC>